A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission
Latest Information Update: 30 Aug 2024
At a glance
- Drugs Azacitidine (Primary)
- Indications Acute myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms QUAZAR AML maintenance; QUAZAR AML-001
- Sponsors Celgene Corporation
- 28 Aug 2024 Status changed from active, no longer recruiting to completed.
- 23 May 2024 According to Bristol Myers Squibb media release, the company announced the presentation of data across its oncology and hematology portfolio at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2024 Hybrid Congress.
- 16 Feb 2024 This trial has been completed in Portugal.